Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
Thank you for registering! Take a moment to confirm your subscription to Insider Trades Newsletter so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.
Send Confirmation Email
NASDAQ:NVUS

Novus Therapeutics (NVUS) Stock Price, News & Analysis

→ Boost your retirement with these AI payouts (From InvestorPlace) (Ad)
Free NVUS Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$2.83
▼
$3.29
50-Day Range
$9.85
▼
$16.50
52-Week Range
$4.50
▼
$27.32
Volume
611,409 shs
Average Volume
78,851 shs
Market Capitalization
$4.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisCompetitorsSocial Media
NVUS stock logo

About Novus Therapeutics Stock (NASDAQ:NVUS)

Novus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.

NVUS Stock News Headlines

March 1, 2024 | morningstar.com
Vivoryon Therapeutics NV VVY
February 22, 2024 | money.usnews.com
Viking Therapeutics Inc
December 28, 2023 | seekingalpha.com
CYT Cyteir Therapeutics, Inc.
May 11, 2023 | finance.yahoo.com
Novo Holdings invests in US$105 million Series C Funding of Alentis Therapeutics
March 31, 2023 | benzinga.com
ProQR Therapeutics Stock (NASDAQ:PRQR), Analyst Ratings, Price Targets, Predictions
March 30, 2023 | finance.yahoo.com
Sales Revenue from CNS Therapeutics Market to Top US$ 142.1 Billion by 2026: Fact.MR Analysis
March 29, 2023 | proactiveinvestors.com
Chimeric Therapeutics welcomes “positive” feedback following pre-IND meeting with US FDA for Phase 1 CAR-T study
March 25, 2023 | usnews.com
East Career Technical Academy
March 25, 2023 | usnews.com
Las Vegas Academy of the Arts
February 22, 2023 | money.usnews.com
Perspective Therapeutics Inc
February 12, 2023 | finance.yahoo.com
Onychomycosis Therapeutics Market Size Worth US$ ~8,420.3 million , Globally, by 2030 at 6% CAGR
See More Headlines

Company Calendar

Last Earnings
11/16/2020
Today
5/20/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NVUS
CUSIP
N/A
CIK
1404281
Web
novustherapeutics.com
Phone
949-238-8090
Fax
N/A
Employees
7
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($21.58)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-16,010,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-133.49%
Return on Assets
-30.52%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
18.78
Quick Ratio
18.78

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$13.13 per share
Price / Book
0.23

Miscellaneous

Outstanding Shares
1,436,000
Free Float
N/A
Market Cap
$4.34 million
Optionable
Not Optionable
Beta
2.07

Key Executives

  • Mr. Jon S. Kuwahara CPA (Age 55)
    CPA, SVP of Fin. & Admin., Principal Financial Officer and Principal Accounting Officer
    Comp: $295.72k
  • Mr. Gregory J. Flesher (Age 50)
    Consultant
    Comp: $482.13k
  • Dr. David-Alexandre C. Gros M.D. (Age 48)
    CEO & Non Independent Director
  • Dr. Steven N. Perrin Ph.D. (Age 55)
    Pres, Chief Scientific Officer & Non Independent Director

Key Competitors

View All Competitors

NVUS Stock Analysis - Frequently Asked Questions

How were Novus Therapeutics' earnings last quarter?

Novus Therapeutics, Inc. (NASDAQ:NVUS) posted its quarterly earnings results on Monday, November, 16th. The biopharmaceutical company reported ($5.51) EPS for the quarter, missing analysts' consensus estimates of ($1.64) by $3.87.
Read the conference call transcript.

When did Novus Therapeutics' stock split?

Shares of Novus Therapeutics reverse split before market open on Monday, October 5th 2020. The 1-18 reverse split was announced on Friday, October 2nd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 2nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

What other stocks do shareholders of Novus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novus Therapeutics investors own include Tonix Pharmaceuticals (TNXP), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), CymaBay Therapeutics (CBAY), Novavax (NVAX), Geron (GERN), Inovio Pharmaceuticals (INO), Verastem (VSTM) and vTv Therapeutics (VTVT).

This page (NASDAQ:NVUS) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners
"The Biggest Drug Ever" Is Coming
Behind the Markets
Exposed: 10 CENT Crypto to Explode May 20th?
True Market Insiders
The 2024 Gold Rush: Unleashing Market Potential
Priority Gold
**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1!
Huge Alerts
Warren Buffett's "mystery stock"
Stansberry Research
This Could be Your “Big Money” AI Moment
InvestorPlace
Digitizing the $11T commodities sector with one tiny stock
Resource Stock Digest
Elon to Transform U.S. Economy?
Porter & Company